


D. Johnson
#6 7-6-00
Priority Papers
Atty. Dkt. No. 0155

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: John C. COX et al

Title: IMMUNOGENIC COMPLEXES
AND METHODS RELATING
THERETO



Appl. No.: 09/506,011

Filing Date: 2/17/2000

Examiner: Unassigned

Art Unit: 1643

CLAIM FOR CONVENTION PRIORITY

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

The benefit of the filing date of the following prior foreign application⁵ filed in the following foreign country is hereby requested, and the right of priority provided in 35 U.S.C. § 119 is hereby claimed.

In support of this claim, filed herewith are certified copies of said original foreign applications:

- Australia Patent Application No. PQ 1861 filed 7/27/1999.
- Australia Patent Application No. PP 8735 filed 2/17/1999.

Respectfully submitted,

Date June 1, 2000

FOLEY & LARDNER
Washington Harbour
3000 K Street, N.W., Suite 500
Washington, D.C. 20007-5109
Telephone: (202) 672-5404
Facsimile: (202) 672-5399

By

A handwritten signature of Stephen A. Bent in black ink.

Stephen A. Bent
Attorney for Applicant
Registration No. 29,768

THIS PAGE BLANK (USPTO)



Patent Office
Canberra

I, KAY WARD, TEAM LEADER EXAMINATION SUPPORT AND SALES hereby certify that annexed is a true copy of the Provisional specification in connection with Application No. PQ 1861 for a patent by CSL LIMITED filed on 27 July 1999.

WITNESS my hand this
Twenty-fifth day of February 2000

K. Ward

KAY WARD
TEAM LEADER EXAMINATION
SUPPORT AND SALES

THIS PAGE BLANK (USPTO)

CSL Limited

A U S T R A L I A
Patents Act 1990

PROVISIONAL SPECIFICATION
for the invention entitled:

"Immunogenic complexes and methods relating thereto - II"

The invention is described in the following statement:

- 1A -

IMMUNOGENIC COMPLEXES AND METHODS RELATING THERETO - II

FIELD OF THE INVENTION

5 The present invention relates generally to an immunogenic complex comprising a charged carrier molecule and a charged antigen and, more particularly, a negatively charged carrier molecule and a positively charged antigen. The complexes of the present invention are useful, *inter alia*, as therapeutic and/or prophylactic agents for facilitating the induction of a cytotoxic T-lymphocyte response to an antigen.

10

BACKGROUND OF THE INVENTION

Bibliographic details of the publications referred to by author in this specification are collected at the end of the description.

15

There is an increasing belief that co-delivery of antigen and adjuvant to the same antigen-presenting-cell (APC) is preferable and sometimes essential for induction of appropriate immune responses. For example, the ability of saponin-based adjuvants to induce CD_8^+ CTL responses is attributed to their ability to cause endosomal escape of antigen, a mechanism
20 which requires co-delivery. Particle formation which comprises a stable complex of adjuvant and antigen is the simplest way to achieve co-delivery. The usefulness of ISCOMTM technology derives partly from the immunomodulatory activity of saponins and partly from their ability to form complexes with hydrophobic or amphipathic immunogens. However, many molecules lack hydrophobic regions and in fact such molecules are preferred as
25 recombinant proteins because of their easier expression and purification.

Accordingly, there is a need to develop immunogenic complexes which facilitate the co-delivery of antigens and carrier molecules which otherwise do not usually form sufficiently stable complexes. For example, complexes comprising antigens which lack hydrophobic
30 regions together with adjuvant.

- 2 -

In work leading up to the present invention, the inventors have developed an immunogenic complex based on the electrostatic association of an antigen and a carrier molecule, such as an adjuvant. This electrostatic association permits co-delivery of the antigen and the carrier molecule to the immune system. Accordingly, by establishing an electrostatic association, 5 antigens of interest (irrespective of their hydrophobicity) can be co-delivered with a carrier molecule, for the purpose, for example, of inducing a cytotoxic T-lymphocyte response to the antigen.

SUMMARY OF THE INVENTION

10

Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.

15

One aspect of the present invention relates to an immunogenic complex comprising a charged carrier molecule and a charged antigen which carrier molecule and antigen are electrostatically associated.

20 Another aspect of the present invention more particularly provides an immunogenic complex comprising a negatively charged carrier molecule and a positively charged antigen which carrier molecule and antigen are electrostatically associated.

Still another aspect of the present invention provides an immunogenic complex comprising 25 a negatively charged carrier molecule and a positively charged protein which carrier molecule and protein are electrostatically associated.

Yet another aspect of the present invention provides an immunogenic complex comprising a negatively charged adjuvant and a positively charged protein which adjuvant and protein are 30 electrostatically associated.

- 3 -

Still yet another aspect of the present invention relates to a vaccine composition comprising as the active component an immunogenic complex comprising a charged carrier molecule and a charged antigen which carrier molecule and antigen are electrostatically associated together with one or more pharmaceutically acceptable carriers and/or diluent.

5

A further aspect of the present invention relates to a method of eliciting, inducing or otherwise facilitating, in a mammal, a cytotoxic T-lymphocyte response to an antigen said method comprising administering to said mammal an effective amount of a vaccine composition as hereinbefore described.

10

Yet another further aspect of the present invention relates to a method of treating a disease condition in a mammal said method comprising administering to said mammal an effective amount of a vaccine composition as hereinbefore described wherein administering said composition elicits, induces or otherwise facilitates an immune response which inhibits, halts,

15 delays or prevents the onset or progression of the disease condition.

Yet another aspect of the present invention relates to the use an immunogenic complex as hereinbefore defined in the manufacture of a medicament for inhibiting, halting or delaying the onset or progression of a disease condition.

20

Still yet another aspect of the present invention relates to an agent for use in inhibiting, halting or delaying the onset or progression of a disease condition. Said agent comprising an immunogenic complex as hereinbefore defined.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1A is a graphical representation of the sucrose gradient analysis of HCV core associated ISCOMATRIX™.

5

Figure 1B is a graphical representation of the sucrose gradient analysis of HCV core protein.

Figure 1C is a graphical representation of the sucrose gradient analysis of ISCOMATRIX™.

10 **Figure 2** is a graphical representation of sucrose gradient analysis of E6E7 associated ISCOMATRIX™.

Figure 3A is a graphical representation of sucrose gradient analysis of NY-ESO-1 associated ISCOMATRIX™.

15

Figure 3B is a graphical representation of sucrose gradient analysis of NY-ESO-1 protein.

Figure 3C is a graphical representation of sucrose gradient analysis of ISCOMATRIX™.

20 **Figure 4** is a graphical representation of antibody responses to NY-ESO-1 formulations.

Figure 5A is a graphical representation of CTL analysis of NY-ESO-1 immunised mice with SLLMWITQCFL peptide.

25 **Figure 5B** is a graphical representation of CTL analysis of NY-ESO-1 associated ISCOMATRIX™ immunised mice with SLLMWITQCFL peptide.

Figure 5C is a graphical representation of CTL analysis of NY-ESO-1 immunised mice with SLLMWITQC peptide.

Figure 5D is a graphical representation of CTL analysis of NY-ESO-1 associated
5 ISCOMATRIX™ immunised mice with SLLMWITQC peptide.

Figure 6 is a graphical representation of the sucrose gradient analysis of ISCOMATRIX™ comprising cardiolipin (Figure 6A), DPPC (Figure 6B) and DPL (Figure 6C). In each case it can be seen that lipid and ³H overlap indicating incorporation of each
10 lipid into the ISCOMATRIX™ structure.

Figure 7 is a graphical representation of the sucrose gradient analysis of two of the ISCOMATRIX™ formulations of Example 7 after mixing with E6E7. It can be seen that E6E7 is strongly associated with cardiolipin ISCOMATRIX™.
15

Figure 8 is a graphical representation of the sucrose gradient analysis of two of the ISCOMATRIX™ formulations of Example 7 after mixing with HpE. It can be seen that HpE is strongly associated with cardiolipin ISCOMATRIX™ but less so with DPPC ISCOMATRIX™.
20

Figure 9 is a graphical representation of the sucrose gradient analysis of two of the ISCOMATRIX™ formulations of Example 7 after mixing with E6E7. It can be seen that E6E7 is strongly associated with DPL ISCOMATRIX™ but less so with DPPC ISCOMATRIX™.
25

Figure 10 is a graphical representation of the sucrose gradient analysis of two of the ISCOMATRIX™ formulations of Example 7 after mixing with ESO-1. It can be seen that most of the ESO-1 is associated with the DPL ISCOMATRIX™ but only part is associated with DPPC ISCOMATRIX™.
30

Figure 11 is a graphical representation of the sucrose gradient analysis of palmitoylated polytope ISCOMS™.

Figure 12 is a graphical representation of the CTL analysis of palmitoylated polytope
5 ISCOMS™.

Figure 13 is a graphical representation of the sucrose gradient analysis of hexa-his polytope ISCOMS™.

10 **Figure 14** is a graphical representation of the CTL analysis of hexa-his polytope ISCOMS™.

Figure 15 is a graphical representation of the sucrose gradient analysis of poly lysine polytope ISCOMS™.

15

Figure 16 is a graphical representation of the CTL analysis of poly lysine polytope ISCOMS™.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

20

The present invention is predicated, in part, on the development of an immunogenic complex formulation which utilises electrostatic interactions to associate an antigen and a carrier molecule thereby facilitating, *inter alia*, the co-delivery of these molecules to the immune system. The immunogenic complexes of the present invention are particularly suitable for
25 use in facilitating the stimulation of cytotoxic T-lymphocyte responses to immunogens which do not comprise hydrophobic regions.

Accordingly, one aspect of the present invention relates to an immunogenic complex comprising a charged carrier molecule and a charged antigen which carrier molecule and
30 antigen are electrostatically associated.

Reference to a "charged" carrier molecule or antigen should be understood as a reference to a carrier molecule or antigen which exhibits an overall positive electrical charge or an overall negative electrical charge. By "overall" is meant the summation of the individual positive and negative charges which a given molecule comprises. Where the summation of the individual positive and negative charges results in overall electrical neutrality, the molecule is not regarded as "charged" within the context of the present invention. Preferably, the antigen comprises an overall positive charge and the carrier molecule comprises an overall negative charge.

- 10 Accordingly, the present invention more particularly provides an immunogenic complex comprising a negatively charged carrier molecule and a positively charged antigen which carrier molecule and antigen are electrostatically associated.

Reference to "electrostatically associated" is a reference to the carrier molecule and the antigen being linked, bound or otherwise associated by means which include electrostatic interaction. Accordingly, it should be understood that in some instances the electrostatic interaction will be the only attractive force which results in complexing of the antigen and the carrier molecule. However, in other instances the formation of the electrostatic interaction may also lead to, or be associated with, the formation of other interactive forces.

20

Reference to "antigen" should be understood as a reference to any molecule against which it is sought to induce an immune response, and in particular, a cytotoxic T-lymphocyte response. The antigen may be either a proteinaceous or a non-proteinaceous molecule, which molecule may or may not be immunogenic if it were administered in isolation. The antigen of the present invention may be naturally derived or it may be recombinantly or synthetically produced. Following its isolation or synthesis the antigen may require further modification (for example, structural or sequence modification to improve its antigenicity) prior to use in the present invention. Antigens suitable for use in the present invention include, but are not limited to, core proteins isolated from viruses, non-core viral proteins, antigens of malignant and non-malignant cells, bacterial antigens, parasite antigens and polytopes..

25
30

Preferably, the antigen is a protein. The term "protein" should be understood to encompass reference to proteins, polypeptides and peptides. The protein may be glycosylated or unglycosylated, phosphorylated or dephosphorylated to various degrees and/or may contain a range of other molecules fused, linked, bound or otherwise associated to the protein such as amino acids, lipids, carbohydrates or other peptides, polypeptides or proteins. Reference hereinafter to a "protein" includes a protein comprising a sequence of amino acids as well as a protein associated with other molecules such as amino acids, lipids, carbohydrates or other peptides, polypeptides or proteins.

- 10 According to this preferred embodiment, there is provided an immunogenic complex comprising a negatively charged carrier molecule and a positively charged protein which carrier molecule and protein are electrostatically associated.

In this regard, the antigen which is included in the immunogenic complex of the present invention may be, in its initial or natural form, positively charged, negatively charged or of neutral charge. Where an antigen is positively charged, it may nevertheless be weakly positively charged and may therefore require modification to increase its degree of positive charge such that complex formation with the negatively charged carrier molecule is better facilitated. For example, wherein an antigen is weakly positively charged, increasing the degree of its positive charge may be achieved by any one of a number of methods known to those skilled in the art including, but not limited to, chemically adding further positive charge to the antigen or recombinantly adding positive charge such as by adding polylysine to the antigen. This is of particular use where the antigen is a protein. Other methods which may be utilised to increase the degree of an antigen's positive charge include, but are not limited to, pH modification, chemical modifications or neutralisation of an antigen's negative charges with positively charged molecules such as arginine. Similarly, where an antigen is neutral or negatively charged, its overall charge can be converted to an overall positive charge by utilising such methodology. Conversion of a negatively charged antigen to express an overall positive charge may be of particular importance where the antigen is a protein, since most proteins are naturally negatively charged.

Once the charge of the antigen of interest is sufficiently positive, it becomes necessary to ensure that precipitation of the positively charged antigen does not occur prior to complex formation with the carrier molecule. In this regard, any suitable method for preventing antigen precipitation may be utilised. For example, antigen solubility may be maintained by
5 disrupting the forces that cause antigen aggregation. Disruption of these forces can be achieved, for example, by incorporating into the antigen solution chaotropic agents such as urea and guanidine, solvents such as DMSO (dimethyl sulfoxide) and acetonitrile, intermediates such as zwitterions, detergents such as Triton X-100 and CHAPS (3-[(3-cholamidopropyl)-dimethylammonio]-2-hydroxy-1-propanesulfonate), reducing agents such
10 as DTT (dithiothreitol) and cysteine and chelating agents such as EDTA (ethylenediaminetetraacetic acid). Solubility can also be maintained by altering the pH of the antigen solution or by chemical modification of the antigen to introduce polar or ionic molecules such as by alkylation or acetylation.

15 Reference to "carrier molecule" should be understood as a reference to any molecule which, when an antigen is associated with it, facilitates the induction of an immune response, and in particular a cytotoxic T-lymphocyte response, to the antigen. In a particularly preferred embodiment the carrier molecule is an adjuvant. By "adjuvant" is meant any molecule or any aggregate or complex of molecules which functions to stimulate, enhance or otherwise up-
20 regulate any one or more aspects of the immune response. For example, the adjuvant may induce inflammation thereby attracting immune response cells to the site of antigen localisation. Alternatively, the adjuvant may slowly release the antigen thereby providing ongoing stimulation of the immune system. Examples of adjuvants suitable for use in the present invention include, but are not limited to, saponin, saponin complexes, any one or
25 more components of the immunostimulating complex of saponin, cholesterol and lipid known as ISCOMATRIXTM (for example the saponin component and/or the phospholipid component), liposomes or oil-in-water emulsions. [The composition and preparation of ISCOMATRIXTM is described in detail in International Patent Application Number PCT/SE86/00480, Australian Patent Numbers 558258 and 632067 and European Patent
30 Publication No. 0 180 564, the disclosures of which are incorporated herein by reference].

Further examples of adjuvants include, but are not limited to, those detailed in the publication of Cox and Coulter, 1992.

Accordingly, the present invention still more preferably provides an immunogenic complex
5 comprising a negatively charged adjuvant and a positively charged protein which adjuvant and protein are electrostatically associated.

Preferably, said adjuvant is saponin or a saponin complex. More preferably, said saponin complex is ISCOMATRIXTM.

10

The carrier molecule of the present invention may also be, in its initial or natural form, negatively charged, positively charged or neutral. Increasing the degree of negative charge (for example, where the carrier molecule is only weakly negatively charged) or converting
15 a neutral or positively charged carrier molecule to a negatively charged carrier molecule may also be achieved by any suitable method known to those skilled in the art. For example, where the carrier is an oil-in-water emulsion, incorporation of any anionic surfactant with a non-polar tail will impart an overall negative charge to the emulsion due to insertion of the tail of the surface of the oil droplet which thereby leaves the negatively charged head group exposed. The negative charge of a saponin complex adjuvant may be increased, for example,
20 by the addition of negatively charged lipid during complex formation.

The present invention is predicated, in part, on the formation of immunogenic complexes via the electrostatic association, preferably, of a negatively charged carrier molecule with a positively charged antigen. The administration of such a complex to a subject facilitates the
25 induction of a significantly better immune response than would be achieved were the adjuvant and antigen administered simultaneously but in a non-associated form. In particular, the administration of an antigen associated with an adjuvant, according to the present invention, facilitates the induction of a cytotoxic T-lymphocyte response to the antigen. However, humoral and other cellular responses can also be enhanced.

30

- 11 -

- Without limiting the present invention to any one theory or mode of action, it is thought that the complexing of the adjuvant with the antigen facilitates co-delivery of the adjuvant and the antigen to the same antigen presenting cell thereby facilitating the induction of immune responses which either would not occur or would not occur as effectively were these
- 5 molecules not co-delivered. For example, the induction of some CD8+ cytotoxic T-lymphocyte responses are thought to occur where the adjuvant induces endosomal escape of the antigen in the antigen presenting cell. This necessarily requires co-delivery of the antigen and the adjuvant to the antigen presenting cell.
- 10 A further aspect of the present invention therefore relates to the use of the invention to induce an immune response in a mammal including, but not limited to, a humoral and/or cell mediated immune response.

- 12 -

Accordingly, another aspect of the present invention relates to a vaccine composition comprising as the active component an immunogenic complex comprising a charged carrier molecule and a charged antigen which carrier molecule and antigen are electrostatically associated together with one or more pharmaceutically acceptable carriers and/or diluent.

5

Preferably, said carrier molecule is an adjuvant, and even more preferably saponin or a saponin complex. Preferably said saponin complex is ISCOMATRIX™.

Still more preferably, said antigen is a protein.

10

Preferably said carrier molecule is negatively charged and said antigen is positively charged.

The pharmaceutical forms suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of
15 sterile injectable solutions or dispersion or may be in the form of a cream or other form suitable for topical application. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol and liquid
20 polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. The preventions of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol,
25 sorbic acid, thimerosal and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminium monostearate and gelatin.

Sterile injectable solutions are prepared by incorporating the active compounds in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filter sterilisation. Generally, dispersions are prepared by incorporating the various sterilised active ingredients into a sterile vehicle which contains the
5 basic dispersion medium and the required other ingredients from those enumerated above.

In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and the freeze-drying technique which yield a powder of the active ingredient plus any additional desired ingredient from previously sterile-filtered solution thereof.

10

When the active ingredients are suitably protected they may be orally administered, for example, with an inert diluent or with an assimilable edible carrier, or it may be enclosed in hard or soft shell gelatin capsule, or it may be compressed into tablets, or it may be incorporated directly with the food of the diet. For oral therapeutic administration, the active
15 compound may be incorporated with excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. Such compositions and preparations should contain at least 1% by weight of active compound. The percentage of the compositions and preparations may, of course, be varied and may conveniently be between about 5 to about 80% of the weight of the unit. The amount of
20 active compound in such therapeutically useful compositions is such that a suitable dosage will be obtained. Preferred compositions or preparations according to the present invention are prepared so that an oral dosage unit form contains between about 0.1 μg and 2000 mg of active compound.

25 The tablets, troches, pills, capsules and the like may also contain the components as listed hereafter: a binder such as gum, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, lactose or saccharin may be added or a flavouring agent such as peppermint, oil of wintergreen, or
30 cherry flavouring. When the dosage unit form is a capsule, it may contain, in addition to

materials of the above type, a liquid carrier. Various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit. For instance, tablets, pills, or capsules may be coated with shellac, sugar or both. A syrup or elixir may contain the active compound, sucrose as a sweetening agent, methyl and propylparabens as
5 preservatives, a dye and flavouring such as cherry or orange flavour. Of course, any material used in preparing any dosage unit form should be pharmaceutically pure and substantially non-toxic in the amounts employed. In addition, the active compound(s) may be incorporated into sustained-release preparations and formulations.

- 10 Without limiting the operation of the present invention in any way, the co-delivery of the immunogenic complex of the present invention is particularly useful for inducing a cytotoxic T-lymphocyte response to an antigen.

Accordingly, still another aspect of the present invention relates to a method of eliciting,
15 inducing or otherwise facilitating, in a mammal, a cytotoxic T-lymphocyte response to an antigen said method comprising administering to said mammal an effective amount of a vaccine composition as hereinbefore described.

A further aspect of the present invention relates to the use of the immunogenic complex of
20 the invention in relation to the therapeutic and/or prophylactic treatment of disease conditions. Examples of disease conditions which can be treated in accordance with the method of the present invention include, but are not limited to, HIV, Hepatitis B, Hepatitis C, melanoma, prostate cancer, breast cancer, tuberculosis and parasitic conditions.

25 Accordingly, yet another aspect of the present invention relates to a method of treating a disease condition in a mammal said method comprising administering to said mammal an effective amount of a vaccine composition as hereinbefore described wherein administering said composition elicits, induces or otherwise facilitates an immune response which inhibits, halts, delays or prevents the onset or progression of the disease condition.

An "effective amount" means an amount necessary at least partly to attain the desired immune response, or to delay the onset or inhibit progression or halt altogether, the onset or progression of a particular condition being treated. This amount varies depending upon the health and physical condition of the individual to be treated, the taxonomic group of individual to be treated, the capacity of the individual's immune system to synthesize antibodies, the degree of protection desired, the formulation of the vaccine, the assessment of the medical situation, and other relevant factors. It is expected that the amount will fall in a relatively broad range that can be determined through routine trials.

10 The term "mammal" includes humans, primates, livestock animals (eg. horses, cattle, sheep, pigs, donkeys), laboratory test animals (eg. mice, rats, rabbits, guinea pigs), companion animals (eg. dogs, cats) and captive wild animals (eg. kangaroos, deer, foxes). Preferably, the mammal is a human or laboratory test animal. Even more preferably, the mammal is a human.

15

The mammal undergoing treatment may be human or an animal in need of therapeutic or prophylactic treatment of a disease condition or a potential disease condition.

In yet another aspect the present invention relates to the use an immunogenic complex as
20 hereinbefore defined in the manufacture of a medicament for inhibiting, halting or delaying the onset or progression of a disease condition.

Yet another aspect of the present invention relates to an agent for use in inhibiting, halting or delaying the onset or progression of a disease condition. Said agent comprising an
25 immunogenic complex as hereinbefore defined.

Further features of the present invention are more fully described in the following Figures and/or Examples.

- 16 -

Reference to "ISCOPREP™ 703" (referred to hereinafter as "703") should be understood as a reference to a saponin preparation comprising from 50-90% by weight of Fraction A of Quil A and 50% to 10% by weight of Fraction C of Quil A. Fractions A and C are prepared from the lipophilic fraction of Quil A. Fractions "A" and "C", their method of preparation and the
5 method of preparing 703 are detailed in International Patent Publication No. WO96/11711, which is incorporated herein by reference.

EXAMPLE 1

10 PREPARATION OF ISCOMATRIX™ (Immunostimulating complexes without immunogen)

ISCOMATRIX™ (Immunostimulating complex without antigen) was prepared essentially by the method of Morein *et al.* (1989). Briefly, to 1.76 ml PBS pH 7.2 was added 0.16 ml of a solution containing 10 mg/ml cholesterol and 10 mg/ml dipalmitylphosphatidylcholine
15 (DPPC) in 20% MEGA-10 detergent (w/v) then 0.08 ml of a solution containing 100 mg/ml 703 in PBS. The solution was held at 25°C for 1 hour with gentle mixing. During subsequent dialysis against PBS/azide, immunostimulating complexes containing cholesterol, DPPC and 703 were formed. This ISCOMATRIX™ was of typical appearance by electron microscopy.

20

EXAMPLE 2

PREPARATION OF ANTIGEN ASSOCIATED ISCOMATRIX™ WITH A NATURALLY POSITIVELY CHARGED PROTEIN : HCV CORE PROTEIN

25 The HCV Core protein has a pI of 11.4 making it a very positively charged protein at pH7.2. Solubility of the HCV core was maintained using 30mM Citrate, 0.23M NaCl, 1mM EDTA, 0.01% Tween 80 at pH5. The HCV Core associated ISCOMATRIX™ formulation was prepared by mixing equal mass of HCV Core and 703 as ISCOMATRIX™ for 60 minutes at 20-25°C.

- 17 -

After formulation, preparations were purified on a sucrose gradient (10 to 50% sucrose w/v) and fractions analysed for protein, association between Core and ISCOMATRIX™ and ISCOMATRIX™ (Figure 1). Protein was detected using the Pierce Coomassie Plus assay according to the manufacturers instructions. Association was determined by EIA using a
5 monoclonal antibody to Core to capture and a HRP conjugate monoclonal antibody to 703 to detect (referred to herein as the "703 assay"). ISCOMATRIX™ was determined by detection of 703 which was assayed for by coating fractions to a microtitre plate then detecting with the HRP conjugated monoclonal antibody to 703.

10 The HCV Core protein, when not mixed with ISCOMATRIX™, was found in fractions 9-12 by the Pierce assay, with negative readings for the association and 703 assays (Figure 1B). ISCOMATRIX™ alone was found in fractions 5-8 by the 703 assay with negative readings in the Pierce and association assays (Figure 1C). The mixture of HCV Core protein and ISCOMATRIX™ showed that both protein and ISCOMATRIX™ were found in the same
15 fractions by the Pierce, association and 703 assays (Figure 1A) indicating association had occurred.

EXAMPLE 3

PREPARATION OF ANTIGEN ASSOCIATED ISCOMATRIX™ WITH A 20 PROTEIN UTILISING pH TO GIVE A POSITIVE CHARGE : HPV E6E7.

The HPV E6E7 fusion protein has a pI of 5.9 making it a negatively charged protein at pH7.2. It contains a hexa histidine sequence at the N terminus which will be positively charged at pH6. Solubility of the E6E7 was maintained using 8M urea, 50mM Bis Tris,
25 0.15M NaCl pH6. The E6E7 associated ISCOMATRIX™ formulation was prepared by mixing equal mass of E6E7 antigen and ISCOMATRIX™ for 60 minutes at 20-25 C, dialysing against 50mM Bis Tris, 0.15M NaCl pH6 to remove the urea then centrifugation at 10,000 g for 5 mins to remove any precipitate.

After formulation, preparations were purified on a sucrose gradient (50 to 10% sucrose w/v) and fractions analysed for protein, association between E6E7 and ISCOMATRIX™ and ISCOMATRIX™ (Figure 2). Protein was detected using a sandwich EIA for E7 with non-competing monoclonal antibodies to capture and detect. Association was determined by EIA
5 using a monoclonal antibody to E7 to capture and a HRP conjugated monoclonal antibody to 703 to detect. ISCOMATRIX™ was determined by detection of dipalmityl phosphatidyl choline (DPPC) using diphenylhexatriene (DPH). Briefly, DPH is dissolved at 1mg/ml in acetone then diluted 1 in 50 in PBS 0.1% azide pH7.2 then 50µl mixed with 50µl of each fraction in a microtitre plate. Following incubation for 150 mins at 20-25°C the plate is read
10 in a microplate fluorometer using excitation 355nm and emission 460nm.

The E6E7 protein was largely confined to fractions 10-15, as measured by the E7 EIA, as was association of E6E7 and 703, as measured by EIA, and approximately half the DPPC, as measured by DPH, indicating association between E6E7 and ISCOMATRIX™. Typically
15 E6E7 protein is found in fractions 2-5 and ISCOMATRIX™ in fractions 10-15 when run separately.

EXAMPLE 4

IMMUNIZATION OF MICE WITH E6E7 ASSOCIATED ISCOMATRIX™.

20

Six C57Bl6 mice were immunized, on days 0 and 21, subcutaneously in the scruff of the neck with 0.1 ml of E6E7 associated ISCOMATRIX™ containing 6µg 703 and 6µg E6E7.

Antibody Responses:

25

Mice were bled on day 26 and sera analysed for antibodies to E7 by indirect EIA. Purified GSTE7 was adsorbed to a microtitre plate in 0.1M Carbonate pH9.6 then the plate blocked with a 0.1% casein solution and dried. Dilutions of sera were incubated for 1 hour at 20-25°C then the plates washed. HRP conjugated goat α mouse IgG was added and plates
30 incubated for 1 hour at 20-25°C then washed. TMB substrate was added and incubated for

- 19 -

10 mins at 20-25°C followed by addition of 0.5M H₂SO₄ to stop the reaction. Plates were read at OD450nm and end point titres calculated.

The E6E7 associated ISCOMATRIX™ group had a GMT of 949. Typically E6E7 with
5 Al(OH)₃ gives a GMT of approximately 100.

Cytokine Responses:

On day 27 splenocytes from each of 3 mice were harvested and pooled and 2.5X10⁶ cells
10 restimulated in 48-well plates with GSTE7 at 1 and 5 µg and ConA and RPMI as controls. Cells were cultured in RPMI media supplemented with 10% foetal calf serum, 2mM glutamine, 5X10⁻⁵ Mβ-mercaptoethanol, 100µg/ml streptomycin and 100IU/ml pencillin and incubated at 37°C for 2 days in 5% CO₂. The supernatant was harvested and γIFN and IL5 detected by EIA using reagents from Endogen according to manufacturers instructions.

15

The E6E7 associated ISCOMATRIX™ induced up to 7.4 ng/ml γIFN and 140 pg/ml IL5 (Table 1). Typically E6E7 with Al(OH)₃ induces no detectable γIFN (<30 pg/ml) or IL5 (<4 pg/ml).

20

EXAMPLE 5

PREPARATION OF ANTIGEN ASSOCIATED ISCOMATRIX™ WITH A NATURALLY POSITIVELY CHARGED PROTEIN : NY-ESO-1 PROTEIN

The NY-ESO-1 protein has a pI of 9.1 making it a very positively charged protein at pH7.2.
25 Solubility of the NY-ESO-1 was maintained using 8M urea. The NY-ESO-1 associated ISCOMATRIX™ formulation was prepared by mixing equal mass of NY-ESO-1 and ISCOMATRIX™ and mixing for 60 minutes at 20-25°C.

After formulation, preparations were purified on a sucrose gradient (10 to 50% sucrose w/v)
30 and fractions analysed for protein, association between NY-ESO-1 and ISCOMATRIX™ and

- 20 -

ISCOMATRIX™ (Figure 3). Protein was detected by EIA using a HRP conjugated monoclonal antibody to NY-ESO-1 to detect fractions adsorbed to a microtitre plate. Association was determined by EIA using a monoclonal antibody to NY-ESO-1 to capture and a HRP conjugated monoclonal antibody to 703 to detect. ISCOMATRIX™ was determined by detection of 703 which was assayed for by coating fractions to a microtitre plate then detecting with the HRP conjugated monoclonal antibody to 703. The NY-ESO-1 protein not mixed with ISCOMATRIX™ was found in fractions 1-5 by protein EIA with negative readings for the association and 703 assays (Figure 3B). ISCOMATRIX™ was found in fractions 4-8 by the 703 assay with negative readings in the protein and association assays (Figure 3C). The mixture of NY-ESO-1 and ISCOMATRIX™ showed protein and 703 in fractions 6-9 by protein, association and 703 EIA's (Figure 3A) indicating association had occurred.

EXAMPLE 6

IMMUNISATION OF MICE WITH NY-ESO-1 FORMULATIONS

Antibody Responses:

Ten BALB/c mice were immunised, on days 0 and 28, subcutaneously in the scruff of the neck with 0.1ml of NY-ESO-1 containing 5µg protein or NY-ESO-1 associated ISCOMATRIX™ containing 5µg protein and 5µg QH. The mice were bled on day 35 and the sera analysed for antibodies to NY-ESO-1 by indirect EIA. The NY-ESO-1 was adsorbed to a microtitre plate in PBS pH7.2 then the plate blocked with a 0.1% casein solution and dried. Dilutions of sera were incubated for 1 hour at 20-25°C then the plates washed. HRP conjugated goat α mouse IgG, IgG₁ or IgG_{2a} was added and plates incubated for 1 hour at 20-25°C then washed. TMB substrate was added and incubated for 10 mins at 20-25°C followed by addition of 0.5M H₂SO₄ to stop the reaction. Plates were read at OD450nm and end point titres calculated.

There was a greater than 20 fold increase in the IgG and IgG₁ responses to NY-ESO-1 when associated with ISCOMATRIX™. Very little IgG_{2a} was induced with NY-ESO-1 alone but when associated with ISCOMATRIX™ there was a thousand fold increase in IgG_{2a} titre.

5 *Cytotoxic T Lymphocyte (CTL) Responses:*

Five HLA A2 transgenic HHD mice were immunised subcutaneously at the base of the tail with 0.1ml of NY-ESO-1 containing 5µg protein or NY-ESO-1 associated ISCOMATRIX™ containing 5µg protein and 5µg QH. After 14 days splenocytes were harvested and 5X10⁶ cells restimulated in 24-well plates with EL4HHD cells sensitised with NY-ESO-1 peptide (10µg/ml for 1 hour 37°C), irradiated and washed twice. Cells were cultured in RPMI media supplemented with 10% foetal calf serum, 2mM glutamine, 5X10⁻⁵ Mβ-mercaptoethanol, 100µg/ml streptomycin and 100IU/ml penicillin and incubated at 37°C for 6 days in 5%CO₂. On day 4 1ml of medium was added containing 5U/ml recombinant human IL-2. On day 6 the cultures were used as effectors in standard 6 hour ⁵¹Chromium release assays against EL4HHD cells sensitised as for restimulation.

CTL were not detected in mice immunised with NY-ESO-1 alone but when associated with ISCOMATRIX™, CTL were detected in all mice (Figure 5).

20

EXAMPLE 7

PREPARATION OF MODIFIED ISCOMATRIX™

(Immunostimulating complexes without immunogen)

ISCOMATRIX™ (Immunostimulating complex without antigen) was prepared essentially by the method of Morein *et al.* (1989). Briefly, to 1.76 ml PBS pH 7.2 was added 0.16 ml of a solution containing 10 mg/ml tritiated (³H) cholesterol and 10 mg/ml either cardiolipin or diphosphoryl lipid A (DPL) in 20% MEGA-10 detergent (w/v) then 0.08 ml of a solution containing 100 mg/ml ISCOPREP™ 703 in PBS. The solution was held at 25°C for 1 hour with gentle mixing. During subsequent dialysis against PBS/azide, immunostimulating

30

- 22 -

complexes are formed. The cardiolipin and DPL ISCOMATRIX™ were of typical appearance by electron microscopy to standard DPPC ISCOMATRIX™.

After formulation, preparations were purified on a sucrose gradient (10 to 50% w/v) and 5 fractions analysed for lipid and cholesterol. Lipid was detected by DPH as described in Example 2 and cholesterol detected by ³Hcpm of 100 µl sample in 1 ml scintillant. The DPH and ³H peaks coincided for all formulations and the gradient profiles were similar indicating incorporation of the cardiolipin or DPL into the ISCOMATRIX™ (Figure 6).

10

EXAMPLE 8

PREPARATION OF ANTIGEN ASSOCIATED CARDOLIPIN ISCOMATRIX™ WITH A NEGATIVELY CHARGED PROTEIN: HPV E6E7

The HPV E6E7 protein has a pI of 5.9 making it a negatively charged protein at pH 6.9. 15 Solubility of the E6E7 was maintained using 8M Urea, 50mM Tris, 50mM NaH₂PO₄·2H₂O, 150mM NaCl pH 6.9. The E6E7 associated ISCOMATRIX™ formulations were prepared by mixing at a 1:5 ratio of protein to ISCOMPREP™ 703 as ISCOMATRIX™ for 60 minutes at 20-25°C.

20 After formulation, preparations were purified on a sucrose gradient (10 to 50% sucrose w/v) and fractions analysed for E6E7, association between E6E7 and ISCOMATRIX™ and ISCOMATRIX™ (Figure 7). E6E7 was detected by EIA using two non-competing monoclonal antibodies to E7. Association was determined by EIA using a monoclonal antibody to E7 to capture and a HRP conjugated monoclonal antibody to ISCOMPREP™ 703 25 to detect. ISCOMATRIX™ was determined by detection of ³H cholesterol.

The E6E7 protein, when not mixed with ISCOMATRIX™, was found in fractions 10-22 by ELA. (Figure 7C). when mixed with standard ISCOMATRIX™ precipitation occurred and the only E6E7 found was in fractions 14 to 20 with no association detected (Figure 7B). 30 When mixed with cardiolipin ISCOMATRIX™ the E6E7 was found in fractions 10 to 16 which

coincided with the association peak and the ISCOMATRIX™ peak which indicates that association occurred (Figure 7A).

EXAMPLE 9

5 **PREPARATION OF ANTIGEN ASSOCIATED CARDOLIPIN ISCOMATRIX™ WITH A POSITIVELY CHARGED PROTEIN: *H. pylori* HpE**

The *H. pylori* HpE protein has a pI of 9.24 making it a positively charged protein at pH 8. Solubility of the Hpe was maintained using 0.5M Tris, 0.5M NaCl, 0.1 % DHPC pH 8. The
10 Hpe associated ISCOMATRIX™ formulations were prepared by mixing at a 1:5 ratio of protein to ISCOPREP™ 703 as ISCOMATRIX™ for 60 minutes at 20-25°C.

After formulation, preparations were purified on a sucrose gradient (10 to 50% sucrose w/v) and fractions analysed for HpE, association between HpE and ISCOMATRIX™ and
15 ISCOMATRIX™ (Figure 8). HpE was detected by adsorbing fractions diluted 1 in 10 in PBS to wells of an EIA plate then detecting with a HRP conjugated monoclonal antibody to Hpe. Association was determined by EIA using a monoclonal antibody to HpE to capture and a HRP conjugated monoclonal antibody to ISCOPREP™ 703 to detect. ISCOMATRIX™ was determined by detection ³H cholesterol.

20

The HpE protein, when not mixed with ISCOMATRIX™, was found in fractions 3-10 by EIA. (Figure 8C). When mixed with standard ISCOMATRIX™ HpE was found throughout the gradient but predominantly in fractions 3 to 9 (Figure 8B). There was association between ISCOMATRIX™ and HpE but at least 50% of the Hpe was not associated. When
25 mixed with cardolipin ISCOMATRIX™ the HpE was found predominantly in fractions 8 to 16 coinciding with the ISCOMATRIX™ and association peaks which indicates that association occurred (Figure 8A). There was very little free HpE in the cardolipin ISCOMATRIX™ formulation but a substantially amount in the standard ISCOMATRIX indicating a higher capacity of the cardolipin ISCOMATRIX™ to associate with antigens that are positively
30 charged.

EXAMPLE 10
PREPARATION OF ANTIGEN ASSOCIATED DPL ISCOMATRIX™
WITH A NEGATIVELY CHARGED PROTEIN: HPV E6E7

5 The HPV E6E7 protein has a pI 5.9 of making it a negatively charged protein at pH 6.9. Solubility of the E6E7 was maintained using 8M Urea, 50mM Tris, 50mM NaH₂PO₄.2H₂O, 150mM NaCl pH 6.9. The E6E7 associated ISCOMATRIX™ formulations were prepared by mixing at a 1:5 ratio of protein to ISCOPREP™ 703 as ISCOMATRIX™ for 60 minutes at 20-25°C.

10

After formulation, preparations were purified on a sucrose gradient (10 to 50% sucrose w/v) and fractions analysed for E6E7, association between E6E7 and ISCOMATRIX™ and ISCOMATRIX™ (Figure 9). E6E7 was detected by EIA using two non-competing monoclonal antibodies to E7. Association was determined by EIA using a monoclonal
15 antibody to E7 to capture and HRP conjugated monoclonal antibody to ISCOPREP™ 703 to detect. ISCOMATRIX™ was determined by detection of ³H cholesterol.

The E6E7 protein, when not mixed with ISCOMATRIX™, was found in fractions 1 to 3 and 15-22 by EIA. (Figure 9C). When mixed with standard ISCOMATRIX™ the profile was
20 essentially the same as protein alone with no indication of association (Figure 9B). When mixed with DPL ISCOMATRIX™ a significant amount of E6E7 was found in fractions 14 to 16 which coincided with the association peak and overlapped with the ISCOMATRIX™ which indicates that association occurred (Figure 9A).

25

EXAMPLE 11
PREPARATION OF ANTIGEN ASSOCIATED ISCOMATRIX™ WITH
A POSITIVELY CHARGED PROTEIN: ESO-1

The ESO-1 protein has a pI of 9.1 making it a positively charged protein at pH 7. Solubility
30 of the ESO-1 was maintained using 8M Urea, 50mM Tris, 50mM NaH₂PO₄.2H₂O, 0.15M

- 25 -

NaCl pH 7. The ESO-1 associated ISCOMATRIX™ formulations were prepared by mixing at a 1:5 ratio of protein to ISCOPREP™ 703 as ISCOMATRIX™ for 60 minutes at 20-25°C.

After formulation, preparations were purified on a sucrose gradient (10 to 50% sucrose w/v) and fractions analysed for ESO-1, association between ESO-1 and ISCOMATRIX™ and ISCOMATRIX™ (Figure 10). ESO-1 was detected by adsorbing fractions diluted 1 in 10 in PBS to wells of a EIA plate then detecting with a HRP conjugated monoclonal antibody to ESO-1. Association was determined by EIA using a monoclonal antibody to ESO-1 to capture and HRP conjugated monoclonal antibody to ISCOPREP™ 703 to detect. ISCOMATRIX™ was determined by detection ³H cholesterol.

The ESO-1 protein, when not mixed with ISCOMATRIX™, was found in fractions 1-6 by EIA. (Figure 10C). When mixed with standard ISCOMATRIX™ ESO-1 was found in fractions 3 to 6 and 12 to 16 (Figure 10B). There was association between the ESO-1 and the ISCOMATRIX™ but at least 60% of the ESO-1 was not associated. When mixed with DPL ISCOMATRIX™ the ESO-1 was found predominantly in fractions 12 to 16 coinciding with the ISCOMATRIX and association peaks which indicates that association occurred (Figure 10A). There was very little free ESO-1 in the DPL ISCOMATRIX™ formulation but a substantial amount in the standard ISCOMATRIX™ indicating a higher capacity of the DPL ISCOMATRIX™ to associate with antigens which are positively charged.

EXAMPLE 12

PREPARATION AND COMPARATIVE ANALYSIS OF A POLY-L-LYSINE POLYTOPE PALMITYFIED POLYTOPE AND HEXA HIS POLYTOPE

25

(a) *Preparation of a synthetic polytope with a palmityl group at the N terminus*

The palmytified polytope was synthesised and purified by Chiron Technologies on Multipin (TM) crowns, as described by Valerio *et al.*, using the Fmoc α-amino protection scheme for the amino acids. After sidechain deprotection and cleavage in a trifluoroacetic acid/scavenger

30

solution, peptides were precipitated with ether and dried. The redissolved peptide was purified by preparative reverse phase HPLC using elution with a gradient of acetonitrile. Fractions containing material of the correct molecular mass, as determined by ion spray mass spectrometry, were pooled and dried.

5

Palmitoyl-L-EEGAIVGEISYIPSAEKITYQRTRALVRPQASGVMPHFMPNTL-OH<400>1 containing four known BALB/c restricted epitopes SYIPSAEKI <400>2, TYQRTRALV <400>3, RPQASGVYM <400>4, YPHFMPTNL <400>5 and a single non BALB/c restricted epitope EEGAIVGEI <400>6 which was added to increase solubility of the polytope.

10

(b) *Preparation of immunostimulating complexes containing a synthetic polytope with a palmitoyl at the N terminus.*

Immunostimulating complex formulations were prepared by the method of Morein *et al.* (1989). Briefly, to 4 mg of polytope solubilised in 1.76 ml 10% MEGA-10 detergent (w/v), 50% Acetonitrile in PBS was added 0.16 ml of a solution containing 10 mg/ml cholesterol and 10 mg/ml dipalmitylphosphatidylcholine (DPPC) in 20% MEGA-10 detergent (w/v) then 0.08 ml of a solution containing 100 mg/ml ISCOPREP™ 703 in PBS. The solution was held at 25°C for 1 hour with gentle mixing. During subsequent dialysis against PBS/azide immunostimulating complexes containing palmitoylated polytope, cholesterol, DPPC and ISCOPREP™ 703 are formed. These immunostimulating complexes were of typical appearance by electron microscopy.

After dialysis, preparations were purified on a sucrose gradient (10 to 50% sucrose w/v) and fractions analysed for lysine and DPPC. Lysine was detected using the CBQCA kit from Molecular Probes and the DPPC detected using diphenylhexatriene DPH. The DPH assay was performed as follows. DPH was dissolved at 1 mg/ml in acetone then diluted 1 in 50 in PBS 0.1% azide pH 7.2 then 50 µl mixed with 50 µl of each fraction in a microtitre plate. Following incubation for 150 minutes at 20-25°C the plate was read in a microplate
30 fluoremeter using excitation 355nm and emission 460nm.

- 27 -

Both lysine and DPPC were found in those fractions in which typical immunostimulating complexes were identified by EM, indicating incorporation of all components into the immunostimulating complex (Figure 11). There was some lysine detected at the top of the gradient which indicated some of the polytope did not incorporate probably due to lack of solubility.

(c) *Immunization of mice with palmitified polytope immunostimulating complexes.*

Three BALB/c mice were immunized subcutaneously at the base of the tail with 0.1 ml of palmitified polytope ISCOM™ containing 6 µg ISCOPREP™ 703 and 3.5 µg protein.

CTL assays were performed according to the method of Elliott *et al.* (1999). Briefly, splenocytes from each spleen were removed on day 14 and cultured in 1 ml medium at 5×10^6 cell/ml, in a 24 well plate, together with 1 µg/ml of the individual peptides (4 peptides/spleen) in a humidified incubator at 37°C. On day 3, 1 ml of fresh media was added and then further *in vitro* restimulation performed on day 7 by adding irradiated (800 rad) peptide sensitised (10 µg/ml, 1 hr 37°C, 2 washes) P815 cells at a responder to stimulator ratio of 20:1 to 2×10^6 effectors/well. The procedure was repeated twice more at 7 day intervals and the bulk cultures were used as effectors 6 days later in a standard 6 hr chromium release assay. Medium contained RPMI 1640 supplemented with 10% FCS (QIMR), 5×10^{-5} M 2-mercaptoethanol, 2mM glutamine and pen/strep antibiotics. Target cells were ^{51}Cr labelled peptide sensitised and unsensitised (control) P815 cells. The ratio of effector:target was 50, 10 and 2 to 1. The assays were performed in 96 well round bottom plates in duplicate.

One mouse responded to all 4 epitopes, another to 3 and the other to 1 epitope (Figure 12).

(d) *Preparation of a synthetic polytope with a hexa-his group at the N terminus.*

The following hexa-his polytope was synthesised and purified as described in part (a).

HHHHHH-L-SYIPSAEKITYQRTRALVRPQASGVYMPHFMTNL-OH <400>7
containing four known BALB/c restricted epitopes SYIPSAEKI <400>2, TYQRTRALV
<400>3, RPQASGVYM <400>4 and YPHFMPTNL <400>5.

5 (e) *Preparation of immunostimulating complexes containing a synthetic polytope with a hexa-his at the N terminus.*

Chelating immunostimulating complexes containing DPIDA were formed as described previously (Macfarlan and Malliaros, 1998). Immunostimulating complexes containing
10 cholesterol, diphosphatidylcholine (DPPC), DPIDA and ISCOPREP™ 703 were formed. These immunostimulating complexes were of typical appearance by electron microscopy.

The hexa-his polytope was associated with the chelating immunostimulating complex according to the process of Macfarlan and Malliaros (1998). Briefly to 2 mg of hexa-his
15 polytope solubilised in 2 ml 8M urea in Tris pH 7.9 was added 2 ml chelating immunostimulating complexes containing 2 mg ISCOPREP™ 703. The solution was held at 20°C for 2 hours then dialysed against PBS.

After dialysis, preparations were purified on a sucrose gradient (10 to 50% sucrose w/v) and
20 fractions analysed for lysine and DPPC. Lysine was detected using the CBQCA kit from Molecular Probes and the DPPC detected using diphenylhexatriene DPH. The DPH assay was performed as follows. DPH was dissolved at 1 mg/ml in acetone then diluted 1 in 50 in PBS 0.1% azide pH 7.2 then 50 µl mixed with 50 µl of each fraction in a microtitre plate. Following incubation for 150 mins at 20-25°C the plate was read in a microplate fluorometer
25 using excitation 355nm and emission 460nm.

Lysine and DPPC were found in those fractions in which typical immunostimulating complexes were identified by EM, indicating incorporation of all components into the immunostimulating complex (Figure 13). There was some lysine detected at the top of the
30 gradient which indicated some of the polytope did not incorporate probably due to lack of

solubility.

(f) Immunization of mice with hexa-his polytope immunostimulating complexes

- 5 Three BALB/c mice were immunized subcutaneously at the base of the tail with 0.1 ml of hexa-his polytope ISCOM™ containing 3 µg ISCOPREP™ 703 and 2 µg protein. CTL assays were performed as described in part (c).

All mice responded to all 4 epitopes with the response to SYIPSAEKI being very weak
10 (Figure 14).

(g) Preparation of a synthetic polytope with a poly lysine group at the N terminus

The following poly lysine polytope was synthesised and purified as described in part (a).

15

KKKKK-L-YPHFMPTNLRPQASGVYMTYQRTRALVSYIPSAEKI-OH <400>8 containing four known BALB/c restricted epitopes, YPHFMPTNL <400>5, RPQASGVYM <400>4, TYQRTRALV <400>3 and SYIPSAEKI <400>2.

- 20 **(h) Preparation of immunostimulating complexes containing a synthetic polytope with poly lysine at the N terminus.**

ISCOMATRIX™ (Immunostimulating complex without antigen) was prepared essentially by the method of Morein *et al.* (1989). Briefly, to 1.76 ml PBS pH 7.2 was added 0.16 ml of
25 a solution containing 10 mg/ml cholesterol and 10 mg/ml dipalmitylphosphatidylcholine (DPPC) in 20% MEGA-10 detergent (w/v) then 0.08 ml of a solution containing 100 mg/ml ISCOPREP™ 703 in PBS. The solution was held at 25°C for 1 hour with gentle mixing. During subsequent dialysis against PBS/azide, immunostimulating complexes containing cholesterol, DPPC and ISCOPREP™ 703 are found. This ISCOMATRIX™ was of typical
30 appearance by electron microscopy.

The poly lysine polytope was solubilised in PBS at 1 mg/ml then associated with the ISCOMATRIX™ by mixing at a ratio of 1:8 for 1 hour at room temperature.

The preparation was purified on a sucrose gradient (10 to 50% sucrose w/v) and fractions
 5 analysed for protein and DPPC. Protein was detected using Coomassie according to the method of Bradford (1976). Briefly 100 µl of each fraction was added to a microplate followed by addition of 100 µl coomassie reagent then the plate read at 595nm. The DPPC was detected using DPH as follows. DPH was dissolved at 1 mg/ml in acetone then diluted 1 in 50 in PBS 0.1% azide pH 7.2 then 50 µl mixed with 50 µl of each fraction in a
 10 microtitre plate. Following incubation for 150 mins at 20-25°C the plate was read in a microplate fluorometer using excitation 355nm and emission 460nm.

Protein and DPPC were found in those fractions in which ISCOMATRIX™ is typically found indicating association of the poly lysine polytope with the ISCOMATRIX™ (Figure 15).

15

(i) Immunization of mice with poly lysine polytope immunostimulating complexes

Five BALB/c mice were immunized subcutaneously at the base of the tail with 0.1 ml of poly lysine polytope ISCOM™ containing 6 µg ISCOPREP™ 703 and 0.75 µg protein. CTL assays
 20 were performed as described in part (c).

All mice responded to all 4 epitopes with the response to SYIPSAEKI <400>2 being very weak (Figure 16).

25 *(j) Conclusion*

Clearly, each of the three formulations were able to induce CTL responses. Although responses to some of the peptides by some of the mice were weak, all mice receiving the hexa-his and polylysine formulations were able to mount a CTL response to each of the 4
 30 CTL epitopes. The consistently weak response by the mice receiving the polylysine

- 31 -

formulation to the SYIPSAEKI epitope could suggest some *in vivo* proteolytic activity which would be expected to affect the outermost peptide to the greatest extent. Responses by this group of mice to the other three peptides were generally very strong.

- 5 Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. It is to be understood that the invention includes all such variations and modifications. The invention also includes all of the steps, features, compositions and compounds referred to or indicated in this specification, individually or collectively, and any and all combinations of any two or more
- 10 of said steps or features.

Table 1 Cytokine Analysis of E6E7 Associated ISCOMATRIX™

	Stimulated with	Concentration µg	Cytokine pg/ml	
			γIFN	IL5
	GSTE7	5	7400	140
15	GSTE7	1	1050	85
	ConA	0.4	2130	74
	RPMI	-	< 30	4

REFERENCES

Bradford, M.M. *Anal. Biochem.* 36:207-212 (1976).

Cox J.C. and Coulter A.R. *Advances in Adjuvant Technology and Application in Animal Parasite Control Utilising Biotechnology*. Chapter 4. Editor Yong, W.K. CRC Press, 1992.

Elliot, S.L., Pye, S., Le, T., Mateo, L., Cox, J., Macdonald, L., Scalzo, A.A., Forbes, C.A. and Suhrbier, A. *Vaccine* 17:2009-2019 (1999).

Macfarlan, R.I. and Mallravos, J. (1998). International Patent Publication No. WO 8/36722.

Morein, B., Lövgren, K. and Hoglund, S., 1989, Immunostimulating complex (ISCOM). In "Vaccines: Recent Trends and Progress." G. Gregoriadis, A.C. Allison and G. Poster (Eds), Plenum Press, New York, p153.

Valerio, R.M., Bray, A.M. and Maeji, N.J., *Int. J. Pept. Prof. Res.* 44:158-165 (1994).

Dated this 27th day of July 1999

CSL Limited

By its Patent Attorneys

Davies Collison Cave

- 1 -

SEQUENCE LISTING

<110> CSL Limited

<120> to be advised

<130> JMS/TDO/LMa

<140>

<141>

<160> 8

<170> PatentIn Ver. 2.0

<210> 1

<211> 9

<212> PRT

<213> mammalian

<400> 1

Glu	Glu	Gly	Ala	Ile	Val	Gly	Glu	Ile	Ser	Tyr	Ile	Pro	Ser	Ala	Glu
1				5				10					15		

Lys	Ile	Thr	Tyr	Gln	Arg	Thr	Arg	Ala	Leu	Val	Arg	Pro	Gln	Ala	Ser
		20					25						30		

Gly	Val	Met	Tyr	Pro	His	Phe	Met	Pro	Thr	Asn	Leu
	35						40				

<210> 2

<211> 9

<212> PRT

<213> mammalian

<400> 2

Ser	Tyr	Ile	Pro	Ser	Ala	Glu	Lys	Ile
1				5				

<210> 3

<211> 9

<212> PRT

<213> mammalian

<400> 3

Thr	Tyr	Gln	Arg	Thr	Arg	Ala	Leu	Val
1				5				

- 2 -

<210> 4
 <211> 9
 <212> PRT
 <213> mammalian

<400> 4
 Arg Pro Gln Ala Ser Gly Val Tyr Met
 1 5

<210> 5
 <211> 9
 <212> PRT
 <213> mammalian

<400> 5
 Tyr Pro His Phe Met Pro Thr Asn Leu
 1 5

<210> 6
 <211> 9
 <212> PRT
 <213> mammalian

<400> 6
 Glu Glu Gly Ala Ile Val Gly Glu Ile
 1 5

<210> 7
 <211> 36
 <212> PRT
 <213> mammalian

<400> 7
 Ser Tyr Ile Pro Ser Ala Glu Lys Ile Thr Tyr Gln Arg Thr Arg Ala
 1 5 10 15


Leu Val Arg Pro Gln Ala Ser Gly Val Tyr Met Tyr Pro His Phe Met
 20 25 30
 Pro Thr Asn Leu
 35

- 3 -

<210> 8
<211> 36
<212> PRT
<213> mammalian


<400> 8
Tyr Pro His Phe Met Pro Thr Asn Leu Arg Pro Gln Ala Ser Gly Val
1 5 10 15
Tyr Met Thr Tyr Gln Arg Thr Arg Ala Leu Val Ser Tyr Ile Pro Ser
20 25 30
Ala Glu Lys Ile
35

Figure 1. Sucrose Gradient Analysis of HCV Core Formulations



THIS PAGE BLANK (USPTO)


Figure 2. Sucrose Gradient Analysis of E6E7 Associated ISCOMATRIX™




THIS PAGE BLANK (USPTO)

Figure 3. Sucrose Gradient Analysis of NY-ESO-1 Formulations.


3A. NY-ESO-1 Associated ISCOMATRIX™



3B. NY-ESO-1 Protein




3C. ISCOMATRIX™



—■— Protein —●— Association —▲— 703

THIS PAGE BLANK (USPTO)

Figure 4. Antibody Response to NY-ESO-1 Formulations.




THIS PAGE BLANK (USPTO)

Figure 5. CTL Analysis of NY-ESO-1 Formulations.


5A. NY-ESO-1

Peptide : SLLMWITQCFL




5B. NY-ESO-1 Associated ISCOMATRIX™

Peptide: SLLMWITQCFL




5C. NY-ESO-1

Peptide: SLLMWITQC




5D. NY-ESO-1 Associated ISCOMATRIX™

Peptide: SLLMWITQC



THIS PAGE BLANK (USPTO)


Figure 6.




THIS PAGE BLANK (USPTO)

Figure 7.


A. Cardiolipin ISCOMATRIX™ + E6E7



B. DPPC ISCOMATRIX™ + E6E7




C. E6E7



—▲— ³H —■— E6E7 —●— Association


THIS PAGE BLANK (USPTO)

Figure 8.




THIS PAGE BLANK (USDT)

Figure 9.




THIS PAGE BLANK (USPTO)

Figure 10.




THIS PAGE BLANK (USPTO)

Figure 11.




THIS PAGE BLANK (USPTO)

Figure 12.




THIS PAGE BLANK (USPTO)

Figure 13.




THIS PAGE BLANK (USPTO)

Figure 14.




THIS PAGE BLANK (USPTO)

Figure 15.



THIS PAGE BLANK (USPTO)

Figure 16.



THIS PAGE BLANK (USPTO)